Nextcure to present trials in progress poster for nc410 at the 2021 american society of clinical oncology (asco) annual meeting

Beltsville, md., may 19, 2021 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator, martin gutierrez, m.d., director, phase 1 program and co-chair of thoracic oncology at hackensack university medical center, will present a trials in progress poster for nc410 at the 2021 american society of clinical oncology (asco) annual meeting.
NXTC Ratings Summary
NXTC Quant Ranking